Results 91 to 100 of about 25,328 (173)

A pharmacovigilance analysis of post-marketing safety of durvalumab

Scientific Reports
Durvalumab has demonstrated significant efficacy in several types of malignancies, while large-scale real-world safety studies remain limited. This study aimed to systematically evaluate the safety of durvalumab through data mining of the U.S.
An-Ju Tan, Wan-Ying Liu, Jun-Li Lu, Qing-Ying Tan, Yu Yan, Dun-Chang Mo   +5 more
doaj   +1 more source

The Efferocytosis‐Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment

MedComm, Volume 7, Issue 11, November 2026.
Efferocytosis is a key process for macrophages to clear apoptotic cells, which undergoes the “ Find Me” chemotaxis signal stage, the “eat me” phagocytosis recognition stage and the “digest me” digestion stage in turn. During the aforementioned three stages, various signaling molecules released by apoptotic cells can promote the phenotypic polarization ...
Qiuping Chen, Chunzhi Wu, Changquan Huang, Hang Zhou   +3 more
wiley   +1 more source

Infusion-Related Reactions Subsequent to Avelumab, Durvalumab, and Atezolizumab Administration: A Retrospective Observational Study

Clinics and Practice
Background: Avelumab, durvalumab, and atezolizumab are anti-programmed death-ligand 1 (PD-L1) antibodies approved for clinical application in Japan. Despite targeting the same molecule, avelumab elicits a different frequency of infusion-related reactions
Keiko Hata, Keina Nakamura, Shinichiro Maeda, Makiko Maeda, Yasushi Fujio, Sachiko Hirobe   +5 more
doaj   +1 more source

Gastric Cancer: Epidemiology, Risk Factors, Pathogenesis, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 11, November 2026.
This comprehensive review summarizes gastric cancer epidemiology, multifactorial risk factors (like infectious, dietary, genetic), pathogenesis such as precancerous evolution, molecular alterations, and a focus on the bidirectional interactions between gastric cancer cells and macrophages in the tumor microenvironment.
Yixuan Xin, Xingya Wang, Yangtao Wu, Qian Liu, Qian Ren, Hui Wang, Jingbo Zhai   +6 more
wiley   +1 more source

Development and Validation of a Gene Expression‐Based Prognostic Model for Patients With Small Cell Lung Cancer Treated With Chemotherapy

MedComm, Volume 7, Issue 11, November 2026.
The SCLC‐PRS model could stratify SCLC patients into high‐risk (PRS‐H) and low‐risk (PRS‐L) groups; PRS‐L patients had significantly longer OS. PRS‐L tumors had increased CD45+ immune infiltration, reduced Tregs/exhausted CD8+ T cells infiltration, and upregulated antigen presentation (MHC‐I/II) expression.
Tingting Liu, Ting Zhou, Silang Mo, Minghui Ge, Wenjuan Ma, JianHua Zhan, Xueyuan Chen, Yuwen Yang, Yuanzhen Ma, Ningning Luo, Wanglong Deng, Yunjie Song, Ran Ding, Yan Huang, Yunpeng Yang, Wenfeng Fang, Dongsheng Chen, Li Zhang, Yuanyuan Zhao   +18 more
wiley   +1 more source

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores

Liver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background & Aims The management of comorbidities has become increasingly relevant in unresectable hepatocellular carcinoma (uHCC) as immunotherapy prolongs survival. Atezolizumab plus bevacizumab (AB) is a standard first‐line option, but bevacizumab carries a risk of cardiovascular toxicities.
Bernardo Stefanini, Lorenza Rimassa, Massimo Iavarone, Giuseppe Cabibbo, Fabio Marra, Caterina Vivaldi, Andrea Dalbeni, Francesca Romana Ponziani, Andrea Palloni, Sara Lonardi, Lorenzo Lani, Piera Federico, Gianluca Svegliati‐Baroni, Tiziana Pressiani, Luca Ielasi, Chiara Mazzarelli, Stefania De Lorenzo, Rodolfo Sacco, Mariangela Bruccoleri, Ciro Celsa, Alessio Mastro, Gianluca Masi, Alessandra Auriemma, Leonardo Stella, Pierluigi Toniutto, Rosanna Villani, Chiara Deiana, Sara Ascari, Mariarosaria Marseglia, Alessandro Granito, Fabio Piscaglia, Francesco Tovoli, on behalf of the ARTE Study Group, Maria Boe, Andrea De Sinno, Federico Ravaioli, Eleonora Alimenti, Lorenzo Canova, Anna Perna, Marco Vicardi, Leonardo A. Natola, Aldo Filice, Filippo Cattazzo, Federica Carlino, Giulia Grassetti, Lucia Cerrito, Francesco Santopaolo, Maria Pallozzi, Maurizio Pompili, Antonio Gasbarrini, Alessio Quartararo, Sofia Calascibetta, Federica Tosi, Arianna Toscano, Claudia Campani, Elisa Pellegrini   +55 more
wiley   +1 more source

Evaluation of early C‐reactive protein kinetics as an early response marker in biliary tract cancer treated with combined chemoimmunotherapy: A multicenter observational study

Cancer, Volume 132, Issue 20, 15 October 2026.
Abstract Background Reliable prognostic biomarkers for treatment response in patients with biliary tract cancer (BTC) who receive chemoimmunotherapy are still lacking. The objective of this study was to evaluate the potential of early C‐reactive protein (CRP) kinetics as a tool for predicting survival in these patients.
Gabriel Allo, Joshua Leutiger, Catherine Leyh, Christian Möhring, Ann‐Kristin Zöller, Vera Himmelsbach, Gianluca Ciarlo, Maryam Barsch, Christoph Neumann‐Haefelin, Bertram Bengsch, Fabian Finkelmeier, Mohamad Murad, Cennet Sahin, Marie‐Luise Berres, Maria A. Gonzalez‐Carmona, Christoph Roderburg, Arndt Weinmann, Anna Saborowski, Arndt Vogel, Dirk Waldschmidt   +19 more
wiley   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1962-1973, 15 October 2026.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Autoimmune encephalitis following treatment with durvalumab for small-cell lung cancer

Journal of International Medical Research
The traditional treatment for small-cell lung cancer (SCLC) has been traditional systemic platinum-containing chemotherapy because the response rate is 50–90%.
Yu-Lan Qian, Ye Jiang, Yin-Hua Gong, Jian-Kang Yu, Chao Liu, Wen-Ting Wu, Dan Shen   +6 more
doaj   +1 more source